Innovative Bladder Cancer Trials Presented at EAU 2026 Congress for Enhanced Patient Care At the EAU 2026 Congress, Photocure presented innovative trials focusing on personalized treatments for bladder cancer, enhancing patient outcomes through advanced methodologies.

Innovative Bladder Cancer Trials Presented at EAU 2026 Congress for Enhanced Patient Care #Norway #Oslo #Bladder_Cancer #Photocure #Hexvix

Photocure's Innovative Trials at EAU 2026 Focus on Tailored Bladder Cancer Treatments Photocure ASA showcases critical trials at EAU 2026 aimed at enhancing personalized care pathways for bladder cancer patients, emphasizing innovative solutions.

Photocure's Innovative Trials at EAU 2026 Focus on Tailored Bladder Cancer Treatments #Norway #Oslo #Bladder_Cancer #Photocure #EAU_2026

Asieris Receives Approval for CEVIRA as the First Non-Invasive Therapy for Cervical Precancerous Lesions in China Asieris Pharmaceuticals has achieved a significant milestone with the approval of CEVIRA in China, marking the first non-invasive therapy for cervical precancerous lesions.

Asieris Receives Approval for CEVIRA as the First Non-Invasive Therapy for Cervical Precancerous Lesions in China #China #N/A #Photocure #CEVIRA #Asieris

Asieris Announces EMA Acceptance for CEVIRA Marketing Authorization in Europe Asieris Pharmaceuticals communicates that the EMA has accepted the application for CEVIRA, a new photodynamic therapy for HSIL. Discover what this means for treatment options in Europe.

Asieris Announces EMA Acceptance for CEVIRA Marketing Authorization in Europe #Norway #Oslo #Photocure #CEVIRA #Asieris

Photocure demonstrates continued growth with its Q4 2025 results. Hexvix/Cysview revenues reached NOK 135.1 million, while commercial EBITDA more than doubled to NOK 8.4 million. The company projects 7-11% product revenue growth for 2026. #Photocure #LifeScience

New Study Highlights Economic Benefits of Blue Light Cystoscopy in Managing Bladder Cancer Across Europe A recent study reveals that the use of blue light cystoscopy (BLC) offers significant clinical and economic advantages for non-muscle-invasive bladder cancer in four European countries.

New Study Highlights Economic Benefits of Blue Light Cystoscopy in Managing Bladder Cancer Across Europe #Norway #Oslo #Bladder_Cancer #Photocure #BLC

Photocure and Intelligent Scopes Corporation Collaborate on AI for Enhanced Bladder Cancer Detection Photocure ASA partners with Intelligent Scopes Corporation to develop AI software for improved bladder cancer diagnosis via blue light cystoscopy. Initial tests are promising.

Photocure and Intelligent Scopes Corporation Collaborate on AI for Enhanced Bladder Cancer Detection #Artificial_Intelligence #Norway #Oslo #Photocure #Intelligent_Scopes

Photocure and Intelligent Scopes Unveil AI-Driven Solutions for Enhanced Bladder Cancer Diagnosis Photocure ASA partners with Intelligent Scopes Corporation to develop innovative AI software for improving bladder cancer detection through blue light cystoscopy.

Photocure and Intelligent Scopes Unveil AI-Driven Solutions for Enhanced Bladder Cancer Diagnosis #Norway #Oslo #Bladder_Cancer #Photocure #Intelligent_Scopes

Photocure ASA Reports Strong Growth in Q1 2025 with Boost in Bladder Cancer Product Sales Photocure ASA has reported impressive growth for Q1 2025, with revenues of NOK 125.3 million and a focus on expanding bladder cancer treatments using innovative technologies.

Photocure ASA Reports Strong Growth in Q1 2025 with Boost in Bladder Cancer Product Sales #Norway #Oslo #Bladder_Cancer #Photocure #Hexvix

Photocure Embraces Change with the Appointment of Jane Healy as New VP and GM for EMEA Photocure has appointed Jane Healy as Vice President and General Manager for the EMEA region. Her extensive background in medical devices aims to enhance growth in uro-oncology.

Photocure Embraces Change with the Appointment of Jane Healy as New VP and GM for EMEA #Norway #Oslo #Bladder_Cancer #Photocure #Jane_Healy

Jane Healy Takes on Leadership Role at Photocure as EMEA General Manager Photocure ASA welcomes Jane Healy as the new Vice President and General Manager for EMEA, bringing extensive medical device expertise to the role.

Jane Healy Takes on Leadership Role at Photocure as EMEA General Manager #Norway #Oslo #Bladder_Cancer #Photocure #Jane_Healy

New BRAVO Study Validates Blue Light Cystoscopy Benefits in Bladder Cancer Treatment The BRAVO study published by Photocure ASA shows that Blue Light Cystoscopy significantly reduces bladder cancer recurrence risk. This real-world evidence strengthens prior clinical findings.

New BRAVO Study Validates Blue Light Cystoscopy Benefits in Bladder Cancer Treatment #Norway #Oslo #Bladder_Cancer #Blue_Light_Cystoscopy #Photocure

Clinical Study Highlights Blue Light Cystoscopy's Role in Lowering Bladder Cancer Recurrence Risk A recent publication sheds light on the significant benefits of Blue Light Cystoscopy in reducing the risk of bladder cancer recurrence, showing a promising 38% reduction compared to white light methods.

Clinical Study Highlights Blue Light Cystoscopy's Role in Lowering Bladder Cancer Recurrence Risk #Norway #Oslo #Bladder_Cancer #Blue_Light_Cystoscopy #Photocure

Photocure and Richard Wolf Unite to Enhance Bladder Cancer Detection with Interim Solution Photocure ASA and Richard Wolf have announced an interim flexible blue light cystoscopy solution for bladder cancer detection, aiding urology centers worldwide.

Photocure and Richard Wolf Unite to Enhance Bladder Cancer Detection with Interim Solution #Norway #Oslo #Bladder_Cancer #Richard_Wolf #Photocure